Precision Oncology Trends
Find the latest precision oncology research trends and breaking stories from Precision Oncology News.
Researchers studied isolated CTCs along with real-world patient data and found that patients with blood-borne HER2 mutations may respond to anti-HER2 treatment.
The company said it is on track to complete a clinical validation by the end of next year, after which it would launch its assay for clinical use.
The two companies will work together to bring the point-of-care pretreatment diagnostic based on the XDX-01 biomarker to market in 2020.
The company is on track to submit Guardant360 to the FDA in the third quarter, but also expects to see pan-cancer reimbursement much sooner.
The company will test samples from women treated with an investigational combination of AstraZeneca's PARP inhibitor olaparib and immunotherapy tremelimumab.
Biocartis' Idylla called some colorectal cancer samples negative that Sysmex Inostics's OncoBEAM called positive, but the clinical implications may be complex.
The firm believes that physicians can use information from the cell-free DNA analyzed by the assay to determine whether to use anti-EGFR drugs during treatment.
The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.
NEC said the deal will bolster its cancer immunotherapy development programs, which are focused on ovarian cancer and head and neck cancer.
The study will explore the ability of the imaging agent to visualize and quantify CD8 T cells in metastatic cancer patients at baseline and after receiving immunotherapies.